A Phase 3 interventional study of Lofexidine in Opioid Withdrawal, sponsored by USWM, LLC (dba US WorldMeds). Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-22.
Sponsored by USWM, LLC (dba US WorldMeds) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.
Eligible subjects (person seeking treatment for partial or total opioid withdrawal) enrolled in this study are required to take lofexidine for a minimum of 7 days.
USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
Drug: Lofexidine
All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
Also known as: Lofexidine hydrochloride (HCL)
Overall Occurrence of Treatment Emergent Adverse Events (TEAEs)
Subjects with at least 1 TEAE occurring on days 1-14.
Time frame: Days 1-14
Overall Occurrence of Serious Treatment Emergent Adverse Events (Serious TEAEs)
Time frame: Days 1-14
Overall Treatment Emergent Adverse Events (TEAEs) by Severity
Time frame: Days 1-14
Occurrence of Per Protocol Adverse Events of Special Interest (AESI)
Time frame: Day 1 to Day 14
Occurrence of Adverse Events (AEs) Not Related to Opioid Withdrawal
Time frame: Day 1 to Day 14
Mean Observed and Change From Screening in Seated Systolic Blood Pressure (mmHg): Vital Sign
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
Time frame: Day 1 to Day 14
Mean Observed and Change From Screening in Standing Systolic Blood Pressure (mmHg): Vital Sign
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
Time frame: Day 1 to Day 14
Mean Observed and Change From Screening in Seated Diastolic Blood Pressure (mmHg): Vital Sign
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
Time frame: Day 1 to Day 14
Mean Observed and Change From Screening in Standing Diastolic Blood Pressure (mmHg): Vital Sign
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
Time frame: Day 1 to Day 14
Mean Observed and Change From Screening in Seated Pulse (Bpm): Vital Signs
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
Time frame: Day 1 to Day 14
Mean Observed and Change From Screening in Standing Pulse (Bpm): Vital Signs
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
Time frame: Day 1 to Day 14
Columbia Suicide Severity Rating Scale Questionnaire (C-SSRS): Suicidal Ideation and Behavior Numbers
The C-SSRS measures both suicidal ideation and suicidal behavior and will be completed to assess lifetime suicidality before first dose of study drug, 3.5 hours after first daily dose of study drug on in-clinic treatment days, and then once a day before dosing during outpatient treatment days. C-SSRS will also be assessed at end of study/discontinuation.
Time frame: Day 1 to Day 14
Clinical Laboratory Test Change From Baseline: Hematology
Hematology Parameters with Shifts in ≥3% of Subjects from Screening to End of Study
Time frame: Day 1 to Day 14
Clinical Laboratory Test Change From Baseline: Chemistry
Chemistry Parameters with Shifts in ≥3% of Subjects from Screening to End of Study
Time frame: Day 1 to Day 14
Clinical Laboratory Test Change From Baseline: Urinalysis
Time frame: Day 1 to Day 7
Safety Electrocardiograms (ECG) Evaluation Shift From Baseline to Post Dose and End of Study
For each 12-lead ECG obtained during the study, the investigator made an overall interpretation of the ECG (normal, abnormal NCS, and abnormal CS). Shifts from normal at baseline to abnormal NCS and abnormal CS at the end of study predose and postdose assessments were summarized.
Time frame: Day 1 and Day 14
| Milestone | OL: Lofexidine HCl |
|---|---|
| Started | 286 |
| Completed | 168 |
| Not completed | 118 |
Subjects with at least 1 TEAE occurring on days 1-14.
| Participants | OL: Lofexidine HCl |
|---|---|
| Overall Occurrence of Treatment Emergent Adverse Events (TEAEs) | 270 |
| Participants | OL: Lofexidine HCl |
|---|---|
| Overall Occurrence of Serious Treatment Emergent Adverse Events (Serious TEAEs) | 2 |
| Participants | OL: Lofexidine HCl |
|---|---|
| Mild | 104 |
| Moderate | 158 |
| Severe | 8 |
| Participants | OL: Lofexidine HCl |
|---|---|
| Orthostatic hypotension | 96 |
| Orthostatic bradycardia | 0 |
| Syncope | 1 |
| Participants | OL: Lofexidine HCl |
|---|---|
| Opioid Withdrawal Related Adverse Events | 233 |
| Non-Opioid Withdrawal Related Adverse Events | 208 |
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
| mmHg | Inpatient: Pre 8AM | Inpatient: 3.5 hr Post 8AM | Inpatient: Pre 1PM | Inpatient: 3.5 hr Post 1PM | Inpatient: Pre 6PM | Inpatient: 3.5 hr Post 6PM | Inpatient: Pre 11PM | Outpatient: Predose | Outpatient: 3.5 hr Postdose |
|---|---|---|---|---|---|---|---|---|---|
| Screening | 121.9 ± 11.85 | — | — | — | — | — | — | — | — |
| Day 1 Observed | 122.2 ± 13.89 | 109.7 ± 15.47 | 111.1 ± 16.07 | 112.6 ± 15.91 | 114.1 ± 15.38 | 116.9 ± 17.94 | 116.7 ± 16.82 | — | — |
| Day 1 Change | — | -12.2 ± 15.25 | -10.8 ± 15.21 | -9.4 ± 16.05 | -8.0 ± 15.12 | -5.2 ± 19.16 | -5.3 ± 17.69 | — | — |
| Day 2 Observed | 116.8 ± 15.77 | 114.8 ± 15.82 | 114.5 ± 14.30 | 115.7 ± 16.20 | 117.4 ± 16.55 | 119.7 ± 18.01 | 117.9 ± 16.04 | — | — |
| Day 2 Change | -5.0 ± 16.21 | -7.0 ± 15.65 | -7.3 ± 15.53 | -6.2 ± 16.43 | -4.5 ± 17.10 | -2.1 ± 18.03 | -3.9 ± 17.24 | — | — |
| Day 3 Observed | 116.0 ± 15.66 | 116.1 ± 15.75 | 114.3 ± 14.71 | 116.9 ± 16.21 | 116.9 ± 15.90 | 118.2 ± 16.64 | 117.1 ± 15.70 | — | — |
| Day 3 Change | -5.9 ± 16.38 | -5.8 ± 16.22 | -7.5 ± 16.40 | -5.0 ± 17.30 | -5.0 ± 16.88 | -3.8 ± 17.08 | -4.9 ± 16.17 | — | — |
| Day 4 Observed | 116.2 ± 15.32 | 113.7 ± 14.26 | 114.4 ± 14.85 | 118.6 ± 14.77 | 118.7 ± 14.68 | 120.0 ± 15.24 | 117.7 ± 13.90 | 117.0 ± 12.44 | 115.7 ± 8.60 |
| Day 4 Change | -6.0 ± 15.47 | -8.1 ± 14.65 | -7.7 ± 14.77 | -3.7 ± 15.31 | -3.0 ± 15.24 | -1.8 ± 16.36 | -4.0 ± 16.10 | -4.7 ± 14.54 | -5.5 ± 11.15 |
| Day 5 Observed | 115.4 ± 14.76 | 114.8 ± 15.06 | 115.2 ± 13.69 | 116.3 ± 15.72 | 117.1 ± 14.78 | 117.2 ± 14.62 | 117.0 ± 13.48 | 116.7 ± 12.12 | 118.3 ± 11.06 |
| Day 5 Change | -6.3 ± 15.86 | -7.1 ± 16.87 | -6.6 ± 15.46 | -5.6 ± 16.76 | -4.8 ± 16.64 | -4.8 ± 15.46 | -4.9 ± 14.93 | -6.3 ± 16.02 | -4.7 ± 14.97 |
| Day 6 Observed | 115.2 ± 16.13 | 113.4 ± 14.81 | 114.0 ± 14.52 | 116.8 ± 16.74 | 116.6 ± 15.03 | 117.5 ± 16.57 | 118.4 ± 16.46 | 118.7 ± 15.19 | 122.0 ± 15.14 |
| Day 6 Change | -6.5 ± 15.89 | -8.7 ± 14.74 | -8.0 ± 14.88 | -5.1 ± 16.57 | -5.5 ± 15.10 | -4.5 ± 17.13 | -3.5 ± 15.41 | -3.6 ± 18.44 | 0.4 ± 19.39 |
| Day 7 Observed | 118.0 ± 16.44 | 116.4 ± 14.82 | 114.9 ± 15.45 | 117.9 ± 11.32 | 117.9 ± 12.20 | 121.1 ± 14.84 | 118.5 ± 12.08 | 120.8 ± 12.99 | 116.3 ± 9.96 |
| Day 7 Change | -4.4 ± 16.50 | -5.4 ± 14.82 | -5.1 ± 12.87 | -3.0 ± 13.44 | -3.0 ± 11.43 | 0.2 ± 15.23 | -1.7 ± 16.30 | 2.6 ± 16.29 | -5.1 ± 12.91 |
| Day 8 Observed | — | — | — | — | — | — | — | 118.4 ± 11.69 | 122.8 ± 13.15 |
| Day 8 Change | — | — | — | — | — | — | — | -2.8 ± 14.03 | 2.1 ± 13.41 |
| Day 9 Observed | — | — | — | — | — | — | — | 124.3 ± 13.14 | 122.3 ± 16.51 |
| Day 9 Change | — | — | — | — | — | — | — | 3.6 ± 14.43 | 1.4 ± 14.75 |
| Day 10 Observed | — | — | — | — | — | — | — | 122.2 ± 14.41 | 124.3 ± 17.24 |
| Day 10 Change | — | — | — | — | — | — | — | 1.2 ± 14.12 | 3.6 ± 17.67 |
| Day 11 Observed | — | — | — | — | — | — | — | 121.2 ± 12.54 | 125.1 ± 14.16 |
| Day 11 Change | — | — | — | — | — | — | — | 0.7 ± 13.52 | 4.6 ± 15.39 |
| Day 12 Observed | — | — | — | — | — | — | — | 126.3 ± 9.75 | 120.4 ± 12.22 |
| Day 12 Change | — | — | — | — | — | — | — | 4.3 ± 9.20 | -1.4 ± 12.10 |
| Day 13 Observed | — | — | — | — | — | — | — | 124.8 ± 12.48 | 123.5 ± 10.61 |
| Day 13 Change | — | — | — | — | — | — | — | 4.0 ± 13.62 | 3.0 ± 14.38 |
| Day 14 Observed | — | — | — | — | — | — | — | 128.0 ± 12.62 | — |
| Day 14 Change | — | — | — | — | — | — | — | 7.6 ± 10.80 | — |
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
| mmHg | Inpatient: Pre 8AM | Inpatient: 3.5 hr Post 8AM | Inpatient: Pre 1PM | Inpatient: 3.5 hr Post 1PM | Inpatient: Pre 6PM | Inpatient: 3.5 hr Post 6PM | Inpatient: Pre 11PM | Outpatient: Predose | Outpatient: 3.5 hr Postdose |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 Observed | 120.4 ± 13.94 | 105.7 ± 16.70 | 107.9 ± 16.43 | 106.7 ± 15.66 | 108.2 ± 16.37 | 108.7 ± 15.75 | 109.0 ± 16.93 | — | — |
| Day 1 Change | — | -16.8 ± 16.80 | -14.3 ± 15.95 | -15.8 ± 16.48 | -14.7 ± 15.80 | -13.9 ± 17.31 | -13.6 ± 17.74 | — | — |
| Day 2 Observed | 112.4 ± 15.85 | 108.5 ± 15.94 | 108.0 ± 15.06 | 108.6 ± 16.90 | 109.8 ± 16.22 | 110.4 ± 17.70 | 110.7 ± 16.07 | — | — |
| Day 2 Change | -10.0 ± 16.32 | -14.0 ± 17.24 | -14.7 ± 16.29 | -14.1 ± 17.11 | -13.0 ± 17.07 | -12.2 ± 17.69 | -11.9 ± 16.91 | — | — |
| Day 3 Observed | 111.2 ± 16.61 | 108.1 ± 17.15 | 109.1 ± 15.40 | 107.8 ± 15.97 | 110.0 ± 15.99 | 110.8 ± 15.77 | 110.5 ± 16.19 | — | — |
| Day 3 Change | -11.4 ± 16.25 | -14.4 ± 17.22 | -13.5 ± 15.73 | -14.8 ± 17.63 | -12.6 ± 17.16 | -11.9 ± 16.61 | -12.2 ± 16.09 | — | — |
| Day 4 Observed | 112.4 ± 15.93 | 107.9 ± 16.18 | 110.9 ± 17.93 | 109.7 ± 14.74 | 112.4 ± 15.12 | 111.7 ± 15.81 | 111.1 ± 14.79 | 116.6 ± 15.11 | 113.4 ± 11.60 |
| Day 4 Change | -10.3 ± 15.29 | -14.4 ± 15.07 | -11.9 ± 16.69 | -13.2 ± 15.66 | -9.9 ± 15.25 | -10.8 ± 16.21 | -11.3 ± 15.89 | -6.1 ± 17.61 | -8.8 ± 13.77 |
| Day 5 Observed | 111.3 ± 15.97 | 108.9 ± 15.41 | 109.2 ± 14.75 | 109.5 ± 15.75 | 110.8 ± 14.72 | 110.2 ± 16.55 | 111.4 ± 15.49 | 114.6 ± 12.29 | 116.1 ± 10.69 |
| Day 5 Change | -11.1 ± 15.19 | -13.6 ± 15.83 | -13.2 ± 16.10 | -13.0 ± 17.91 | -11.7 ± 16.44 | -12.3 ± 17.23 | -11.0 ± 16.42 | -8.4 ± 14.43 | -7.5 ± 15.02 |
| Day 6 Observed | 112.2 ± 16.44 | 108.8 ± 15.61 | 110.2 ± 15.25 | 109.1 ± 16.83 | 110.7 ± 16.44 | 110.9 ± 16.91 | 112.7 ± 16.24 | 116.6 ± 15.47 | 116.4 ± 16.05 |
| Day 6 Change | -10.4 ± 16.12 | -14.0 ± 17.01 | -12.6 ± 15.30 | -13.8 ± 17.45 | -12.3 ± 16.78 | -12.0 ± 17.84 | -10.0 ± 16.10 | -5.8 ± 17.68 | -5.8 ± 18.68 |
| Day 7 Observed | 113.9 ± 17.10 | 113.9 ± 14.96 | 110.1 ± 17.41 | 110.1 ± 15.32 | 112.7 ± 13.26 | 114.6 ± 16.42 | 111.6 ± 14.00 | 118.0 ± 13.00 | 116.6 ± 15.53 |
| Day 7 Change | -8.7 ± 17.74 | -8.2 ± 16.40 | -8.8 ± 16.55 | -9.6 ± 17.71 | -6.8 ± 14.10 | -4.6 ± 17.96 | -7.3 ± 17.01 | -4.6 ± 15.53 | -5.8 ± 19.56 |
| Day 8 Observed | — | — | — | — | — | — | — | 117.8 ± 11.13 | 117.6 ± 13.94 |
| Day 8 Change | — | — | — | — | — | — | — | -2.8 ± 13.53 | -2.5 ± 18.18 |
| Day 9 Observed | — | — | — | — | — | — | — | 119.4 ± 10.62 | 119.5 ± 17.05 |
| Day 9 Change | — | — | — | — | — | — | — | -0.8 ± 13.27 | -0.9 ± 21.35 |
| Day 10 Observed | — | — | — | — | — | — | — | 122.3 ± 14.78 | 121.9 ± 18.78 |
| Day 10 Change | — | — | — | — | — | — | — | 1.6 ± 15.46 | 1.6 ± 22.89 |
| Day 11 Observed | — | — | — | — | — | — | — | 123.7 ± 14.91 | 123.2 ± 14.43 |
| Day 11 Change | — | — | — | — | — | — | — | 3.0 ± 16.20 | 1.8 ± 18.90 |
| Day 12 Observed | — | — | — | — | — | — | — | 124.3 ± 11.19 | 118.4 ± 14.06 |
| Day 12 Change | — | — | — | — | — | — | — | 2.0 ± 12.76 | -4.1 ± 16.91 |
| Day 13 Observed | — | — | — | — | — | — | — | 122.7 ± 11.77 | 125.1 ± 12.25 |
| Day 13 Change | — | — | — | — | — | — | — | 1.0 ± 14.58 | 3.5 ± 16.41 |
| Day 14 Observed | — | — | — | — | — | — | — | 128.8 ± 9.89 | — |
| Day 14 Change | — | — | — | — | — | — | — | 7.8 ± 9.92 | — |
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
| mmHg | Inpatient: Pre 8AM | Inpatient: 3.5 hr Post 8AM | Inpatient: Pre 1PM | Inpatient: 3.5 hr Post 1PM | Inpatient: Pre 6PM | Inpatient: 3.5 hr Post 6PM | Inpatient: Pre 11PM | Outpatient: Predose | Outpatient: 3.5 hr Postdose |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 Observed | 78.3 ± 8.89 | 69.4 ± 10.95 | 69.3 ± 10.34 | 70.8 ± 11.13 | 71.5 ± 10.76 | 73.5 ± 12.18 | 72.8 ± 12.26 | — | — |
| Day 1 Change | NA ± NA | -7.8 ± 10.78 | -7.9 ± 9.88 | -6.3 ± 11.49 | -5.7 ± 10.80 | -3.7 ± 12.52 | -4.3 ± 12.55 | — | — |
| Day 2 Observed | 73.8 ± 10.49 | 72.2 ± 10.89 | 72.2 ± 10.20 | 73.4 ± 11.53 | 73.7 ± 12.08 | 75.4 ± 11.67 | 74.0 ± 11.44 | — | — |
| Day 2 Change | -3.3 ± 10.73 | -4.9 ± 11.17 | -5.0 ± 10.61 | -3.8 ± 11.38 | -3.4 ± 12.04 | -1.8 ± 12.19 | -3.3 ± 12.11 | — | — |
| Day 3 Observed | 73.7 ± 11.05 | 73.2 ± 10.59 | 71.4 ± 10.05 | 73.0 ± 10.48 | 72.9 ± 10.64 | 73.2 ± 11.32 | 73.5 ± 11.08 | — | — |
| Day 3 Change | -3.6 ± 11.60 | -4.0 ± 10.97 | -5.8 ± 10.88 | -4.1 ± 10.32 | -4.3 ± 10.56 | -4.0 ± 11.41 | -3.8 ± 11.37 | — | — |
| Day 4 Observed | 73.9 ± 10.55 | 71.4 ± 10.28 | 70.9 ± 11.11 | 74.7 ± 10.39 | 73.7 ± 10.10 | 74.0 ± 10.95 | 73.4 ± 9.78 | 75.0 ± 8.57 | 71.7 ± 8.53 |
| Day 4 Change | -3.2 ± 11.06 | -5.7 ± 10.75 | -6.4 ± 10.48 | -2.6 ± 10.27 | -3.3 ± 9.74 | -3.1 ± 11.75 | -3.6 ± 10.51 | -3.0 ± 10.65 | -6.1 ± 10.68 |
| Day 5 Observed | 73.2 ± 10.42 | 71.5 ± 10.25 | 71.7 ± 10.38 | 72.7 ± 10.58 | 71.8 ± 10.14 | 73.1 ± 9.97 | 72.3 ± 10.44 | 72.6 ± 9.99 | 72.8 ± 10.67 |
| Day 5 Change | -3.8 ± 11.17 | -5.4 ± 11.75 | -5.1 ± 10.59 | -4.2 ± 10.38 | -5.0 ± 10.79 | -3.7 ± 10.77 | -4.7 ± 10.56 | -5.6 ± 11.18 | -6.0 ± 12.01 |
| Day 6 Observed | 72.2 ± 10.33 | 69.8 ± 10.46 | 70.8 ± 10.81 | 72.2 ± 10.08 | 72.6 ± 11.02 | 72.8 ± 11.35 | 72.0 ± 11.29 | 74.2 ± 11.25 | 76.8 ± 9.99 |
| Day 6 Change | -4.6 ± 9.87 | -7.0 ± 10.86 | -6.0 ± 11.42 | -4.6 ± 10.46 | -4.3 ± 10.77 | -4.0 ± 11.05 | -4.9 ± 11.51 | -3.9 ± 12.17 | -1.4 ± 12.90 |
| Day 7 Observed | 72.9 ± 10.63 | 74.3 ± 9.90 | 71.5 ± 11.18 | 70.2 ± 10.40 | 70.0 ± 9.09 | 73.1 ± 9.62 | 69.8 ± 8.04 | 76.1 ± 9.30 | 71.8 ± 8.90 |
| Day 7 Change | -3.6 ± 11.56 | -3.5 ± 10.59 | -4.8 ± 12.01 | -6.9 ± 10.96 | -7.6 ± 10.25 | -4.5 ± 10.21 | -7.5 ± 12.94 | -2.6 ± 11.32 | -7.6 ± 14.12 |
| Day 8 Observed | — | — | — | — | — | — | — | 73.5 ± 9.23 | 73.9 ± 11.18 |
| Day 8 Change | — | — | — | — | — | — | — | -4.1 ± 10.98 | -3.5 ± 13.10 |
| Day 9 Observed | — | — | — | — | — | — | — | 75.5 ± 9.38 | 74.0 ± 11.92 |
| Day 9 Change | — | — | — | — | — | — | — | -1.7 ± 10.71 | -3.5 ± 12.63 |
| Day 10 Observed | — | — | — | — | — | — | — | 74.6 ± 9.44 | 75.8 ± 12.46 |
| Day 10 Change | — | — | — | — | — | — | — | -2.4 ± 9.31 | -1.2 ± 12.34 |
| Day 11 Observed | — | — | — | — | — | — | — | 75.7 ± 10.37 | 76.3 ± 8.99 |
| Day 11 Change | — | — | — | — | — | — | — | -0.9 ± 11.57 | -0.4 ± 10.87 |
| Day 12 Observed | — | — | — | — | — | — | — | 77.3 ± 8.01 | 76.6 ± 8.26 |
| Day 12 Change | — | — | — | — | — | — | — | 0.6 ± 10.39 | -0.5 ± 9.47 |
| Day 13 Observed | — | — | — | — | — | — | — | 77.2 ± 8.22 | 77.9 ± 8.98 |
| Day 13 Change | — | — | — | — | — | — | — | 1.3 ± 10.94 | 2.0 ± 13.71 |
| Day 14 Observed | — | — | — | — | — | — | — | 78.4 ± 7.81 | — |
| Day 14 Change | — | — | — | — | — | — | — | 3.5 ± 9.72 | — |
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
| mmHg | Inpatient: Pre 8AM | Inpatient: 3.5 hr Post 8AM | Inpatient: Pre 1PM | Inpatient: 3.5 hr Post 1PM | Inpatient: Pre 6PM | Inpatient: 3.5 hr Post 6PM | Inpatient: Pre 11PM | Outpatient: Predose | Outpatient: 3.5 hr Postdose |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 Observed | 79.8 ± 8.65 | 68.8 ± 11.34 | 70.3 ± 11.03 | 69.8 ± 11.87 | 70.7 ± 11.25 | 71.0 ± 11.12 | 70.4 ± 11.68 | — | — |
| Day 1 Change | — | -11.1 ± 11.58 | -9.5 ± 11.26 | -10.0 ± 12.57 | -9.4 ± 11.73 | -8.9 ± 12.71 | -9.6 ± 12.92 | — | — |
| Day 2 Observed | 73.4 ± 11.02 | 70.7 ± 11.20 | 71.0 ± 11.48 | 71.6 ± 11.85 | 72.2 ± 11.78 | 72.3 ± 12.27 | 71.8 ± 11.52 | — | — |
| Day 2 Change | -6.5 ± 11.83 | -9.4 ± 12.26 | -9.1 ± 12.74 | -8.5 ± 12.48 | -7.9 ± 13.00 | -7.9 ± 13.44 | -8.4 ± 13.05 | — | — |
| Day 3 Observed | 74.0 ± 12.03 | 70.6 ± 11.90 | 70.0 ± 10.53 | 70.0 ± 10.62 | 70.8 ± 10.77 | 71.3 ± 10.69 | 71.5 ± 10.90 | — | — |
| Day 3 Change | -6.2 ± 12.37 | -9.4 ± 13.09 | -10.0 ± 11.74 | -10.1 ± 11.91 | -9.3 ± 12.00 | -8.8 ± 11.91 | -8.7 ± 11.78 | — | — |
| Day 4 Observed | 73.2 ± 11.80 | 70.6 ± 11.11 | 71.2 ± 11.12 | 71.5 ± 10.98 | 72.2 ± 10.59 | 71.2 ± 11.09 | 71.8 ± 10.14 | 75.7 ± 10.45 | 70.1 ± 10.26 |
| Day 4 Change | -7.0 ± 12.08 | -9.4 ± 11.90 | -9.2 ± 11.96 | -8.9 ± 12.91 | -8.0 ± 11.71 | -9.0 ± 12.64 | -8.2 ± 11.46 | -4.5 ± 13.21 | -10.0 ± 11.81 |
| Day 5 Observed | 72.4 ± 10.04 | 70.0 ± 10.46 | 70.7 ± 10.76 | 70.3 ± 10.99 | 71.1 ± 11.38 | 70.2 ± 11.20 | 71.1 ± 10.94 | 74.8 ± 9.79 | 74.5 ± 10.44 |
| Day 5 Change | -7.6 ± 11.99 | -10.0 ± 11.47 | -9.2 ± 12.07 | -9.6 ± 13.00 | -8.7 ± 12.76 | -9.8 ± 12.01 | -9.0 ± 11.39 | -5.5 ± 10.70 | -6.3 ± 12.07 |
| Day 6 Observed | 72.9 ± 10.11 | 69.3 ± 10.11 | 71.1 ± 10.70 | 70.2 ± 11.15 | 71.4 ± 11.43 | 72.1 ± 12.37 | 72.5 ± 11.07 | 74.1 ± 12.33 | 73.2 ± 11.31 |
| Day 6 Change | -7.1 ± 11.40 | -10.7 ± 12.20 | -8.9 ± 11.60 | -9.8 ± 12.77 | -8.6 ± 12.26 | -7.9 ± 13.33 | -7.5 ± 11.88 | -6.1 ± 13.61 | -6.8 ± 14.08 |
| Day 7 Observed | 73.6 ± 11.16 | 73.2 ± 11.07 | 70.3 ± 11.17 | 71.3 ± 11.69 | 70.4 ± 11.25 | 72.5 ± 10.89 | 69.0 ± 8.93 | 77.1 ± 11.43 | 70.8 ± 11.27 |
| Day 7 Change | -6.2 ± 12.37 | -7.4 ± 11.17 | -9.5 ± 9.83 | -9.7 ± 12.29 | -10.8 ± 11.06 | -8.5 ± 12.94 | -11.8 ± 11.89 | -3.3 ± 12.24 | -10.4 ± 15.57 |
| Day 8 Observed | — | — | — | — | — | — | — | 74.6 ± 9.22 | 74.5 ± 13.60 |
| Day 8 Change | — | — | — | — | — | — | — | -5.8 ± 10.46 | -6.2 ± 14.23 |
| Day 9 Observed | — | — | — | — | — | — | — | 78.4 ± 9.63 | 76.5 ± 14.02 |
| Day 9 Change | — | — | — | — | — | — | — | -1.8 ± 10.89 | -4.2 ± 13.95 |
| Day 10 Observed | — | — | — | — | — | — | — | 76.9 ± 10.41 | 75.9 ± 11.86 |
| Day 10 Change | — | — | — | — | — | — | — | -3.2 ± 10.32 | -4.5 ± 12.68 |
| Day 11 Observed | — | — | — | — | — | — | — | 78.1 ± 11.01 | 76.0 ± 9.55 |
| Day 11 Change | — | — | — | — | — | — | — | -1.7 ± 10.96 | -3.9 ± 9.81 |
| Day 12 Observed | — | — | — | — | — | — | — | 80.0 ± 8.12 | 78.7 ± 9.55 |
| Day 12 Change | — | — | — | — | — | — | — | 0.3 ± 8.62 | -1.6 ± 11.95 |
| Day 13 Observed | — | — | — | — | — | — | — | 83.6 ± 8.38 | 80.8 ± 8.69 |
| Day 13 Change | — | — | — | — | — | — | — | 4.5 ± 10.29 | 1.1 ± 12.01 |
| Day 14 Observed | — | — | — | — | — | — | — | 84.8 ± 8.53 | — |
| Day 14 Change | — | — | — | — | — | — | — | 5.5 ± 9.72 | — |
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
| beats per minute (bpm) | Inpatient: Pre 8AM | Inpatient: 3.5 hr Post 8AM | Inpatient: Pre 1PM | Inpatient: 3.5 hr Post 1PM | Inpatient: Pre 6PM | Inpatient: 3.5 hr Post 6PM | Inpatient: Pre 11PM | Outpatient: Predose | Outpatient: 3.5 hr Postdose |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 Observed | 73.3 ± 10.89 | 68.8 ± 11.92 | 69.2 ± 11.08 | 69.9 ± 12.57 | 70.5 ± 12.28 | 67.6 ± 12.55 | 67.7 ± 12.08 | — | — |
| Day 1 Change | NA ± NA | -6.1 ± 12.75 | -5.7 ± 12.11 | -4.9 ± 13.47 | -4.3 ± 13.63 | -7.3 ± 13.59 | -7.0 ± 12.82 | — | — |
| Day 2 Observed | 70.2 ± 12.70 | 68.8 ± 12.36 | 69.4 ± 11.57 | 66.8 ± 12.65 | 68.7 ± 12.11 | 65.9 ± 12.41 | 66.4 ± 12.55 | — | — |
| Day 2 Change | -4.7 ± 14.21 | -5.9 ± 14.63 | -5.4 ± 13.64 | -8.0 ± 14.53 | -6.2 ± 13.75 | -9.1 ± 14.30 | -8.6 ± 14.30 | — | — |
| Day 3 Observed | 213 ± 70.0 | 67.5 ± 12.97 | 68.7 ± 11.57 | 66.6 ± 12.03 | 68.3 ± 12.23 | 65.9 ± 11.68 | 67.4 ± 12.01 | — | — |
| Day 3 Change | -5.0 ± 15.10 | -7.5 ± 15.52 | -6.4 ± 14.42 | -8.5 ± 14.77 | -6.8 ± 14.26 | -9.2 ± 14.25 | -7.8 ± 13.70 | — | — |
| Day 4 Observed | 70.1 ± 13.60 | 68.3 ± 12.46 | 70.6 ± 12.98 | 67.8 ± 13.00 | 70.0 ± 12.01 | 67.8 ± 13.80 | 69.9 ± 12.80 | 70.6 ± 11.83 | 72.4 ± 12.46 |
| Day 4 Change | -5.0 ± 16.11 | -6.8 ± 15.56 | -4.5 ± 15.43 | -7.3 ± 15.44 | -5.0 ± 15.35 | -6.8 ± 16.59 | -4.5 ± 14.74 | -5.2 ± 13.76 | -3.3 ± 13.25 |
| Day 5 Observed | 70.9 ± 13.70 | 69.1 ± 11.03 | 71.4 ± 11.78 | 69.0 ± 13.35 | 68.7 ± 11.08 | 68.3 ± 12.84 | 70.0 ± 11.20 | 76.3 ± 13.49 | 73.3 ± 11.44 |
| Day 5 Change | -3.4 ± 16.28 | -5.3 ± 13.57 | -2.8 ± 13.92 | -5.2 ± 15.23 | -5.5 ± 12.29 | -6.0 ± 15.26 | -4.4 ± 13.53 | -0.3 ± 15.14 | -3.2 ± 13.70 |
| Day 6 Observed | 70.5 ± 11.24 | 69.8 ± 12.46 | 70.6 ± 12.24 | 68.6 ± 11.43 | 69.7 ± 10.67 | 68.9 ± 13.05 | 71.2 ± 12.43 | 75.2 ± 12.24 | 74.8 ± 13.10 |
| Day 6 Change | -3.6 ± 14.98 | -4.1 ± 14.44 | -3.3 ± 13.62 | -5.3 ± 14.37 | -4.3 ± 12.88 | -5.1 ± 14.79 | -2.8 ± 13.55 | -1.6 ± 14.82 | -1.6 ± 14.29 |
| Day 7 Observed | 73.2 ± 13.34 | 73.9 ± 11.70 | 73.6 ± 11.55 | 73.0 ± 12.53 | 73.6 ± 11.74 | 67.4 ± 13.44 | 69.8 ± 11.59 | 73.6 ± 11.46 | 67.1 ± 8.84 |
| Day 7 Change | -1.1 ± 16.86 | 0.0 ± 13.60 | -3.1 ± 13.15 | -3.8 ± 12.93 | -3.4 ± 11.72 | -9.5 ± 13.96 | 24 ± 13.29 | -3.4 ± 15.07 | -7.7 ± 10.63 |
| Day 8 Observed | — | — | — | — | — | — | — | 77.7 ± 12.71 | 72.6 ± 13.45 |
| Day 8 Change | — | — | — | — | — | — | — | 1.6 ± 15.25 | -3.8 ± 13.48 |
| Day 9 Observed | — | — | — | — | — | — | — | 79.6 ± 10.77 | 75.1 ± 11.19 |
| Day 9 Change | — | — | — | — | — | — | — | 2.8 ± 11.80 | -1.7 ± 11.18 |
| Day 10 Observed | — | — | — | — | — | — | — | 80.0 ± 13.29 | 77.9 ± 16.42 |
| Day 10 Change | — | — | — | — | — | — | — | 3.2 ± 14.82 | 1.1 ± 16.97 |
| Day 11 Observed | — | — | — | — | — | — | — | 79.3 ± 13.93 | 74.5 ± 12.49 |
| Day 11 Change | — | — | — | — | — | — | — | 3.2 ± 13.40 | -1.4 ± 12.92 |
| Day 12 Observed | — | — | — | — | — | — | — | 79.7 ± 11.89 | 72.3 ± 11.68 |
| Day 12 Change | — | — | — | — | — | — | — | 4.0 ± 14.22 | -3.6 ± 12.29 |
| Day 13 Observed | — | — | — | — | — | — | — | 76.6 ± 13.20 | 75.5 ± 13.61 |
| Day 13 Change | — | — | — | — | — | — | — | 2.4 ± 14.79 | 0.8 ± 11.75 |
| Day 14 Observed | — | — | — | — | — | — | — | 76.4 ± 11.66 | — |
| Day 14 Change | — | — | — | — | — | — | — | 2.4 ± 14.27 | — |
Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.
| beats per minute (bpm) | Inpatient: Pre 8AM | Inpatient: 3.5 hr Post 8AM | Inpatient: Pre 1PM | Inpatient: 3.5 hr Post 1PM | Inpatient: Pre 6PM | Inpatient: 3.5 hr Post 6PM | Inpatient: Pre 11PM | Outpatient: Predose | Outpatient: 3.5 hr Postdose |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 Observed | 82.8 ± 13.74 | 79.6 ± 14.29 | 80.1 ± 13.72 | 81.3 ± 14.42 | 81.2 ± 14.17 | 78.9 ± 14.14 | 79.4 ± 14.03 | — | — |
| Day 1 Change | NA ± NA | -1.8 ± 15.18 | -1.3 ± 14.38 | 0.0 ± 16.41 | -0.1 ± 15.89 | -2.5 ± 16.25 | -1.8 ± 16.00 | — | — |
| Day 2 Observed | 82.4 ± 15.13 | 80.6 ± 15.19 | 81.1 ± 13.74 | 80.5 ± 14.44 | 80.8 ± 14.46 | 78.0 ± 14.67 | 78.4 ± 13.95 | — | — |
| Day 2 Change | 1.0 ± 16.81 | -0.5 ± 17.61 | 0.0 ± 16.22 | -0.6 ± 15.44 | -0.4 ± 16.00 | -3.3 ± 16.49 | -3.0 ± 16.62 | — | — |
| Day 3 Observed | 81.1 ± 14.82 | 79.0 ± 14.24 | 80.0 ± 14.67 | 78.1 ± 15.09 | 79.1 ± 15.36 | 76.4 ± 13.75 | 78.3 ± 13.92 | — | — |
| Day 3 Change | -0.2 ± 16.77 | -2.6 ± 16.59 | -1.5 ± 15.95 | -3.3 ± 17.08 | -2.3 ± 16.27 | -5.0 ± 16.31 | -3.2 ± 16.32 | — | — |
| Day 4 Observed | 81.2 ± 14.93 | 80.1 ± 14.67 | 81.5 ± 15.40 | 79.9 ± 15.42 | 80.8 ± 16.34 | 78.2 ± 15.52 | 80.4 ± 16.16 | 82.0 ± 11.75 | 83.3 ± 15.43 |
| Day 4 Change | -0.2 ± 16.09 | -1.3 ± 16.36 | 0.0 ± 16.85 | -1.5 ± 17.75 | -0.7 ± 18.62 | -2.7 ± 17.29 | -0.2 ± 17.49 | 0.9 ± 15.06 | 2.1 ± 18.73 |
| Day 5 Observed | 83.1 ± 16.31 | 81.0 ± 14.06 | 82.3 ± 15.43 | 84.7 ± 51.39 | 80.2 ± 14.86 | 79.5 ± 14.08 | 80.6 ± 14.74 | 85.2 ± 15.23 | 80.8 ± 14.81 |
| Day 5 Change | 2.4 ± 18.58 | 0.3 ± 15.33 | 1.6 ± 16.77 | 4.2 ± 50.96 | -0.4 ± 14.80 | -1.2 ± 15.68 | -0.1 ± 16.33 | 2.8 ± 16.75 | -1.7 ± 15.90 |
| Day 6 Observed | 81.7 ± 14.96 | 79.9 ± 14.89 | 81.8 ± 14.90 | 79.5 ± 14.00 | 81.5 ± 13.93 | 80.9 ± 14.54 | 80.9 ± 15.77 | 86.4 ± 15.08 | 84.8 ± 14.77 |
| Day 6 Change | 1.4 ± 16.05 | -0.5 ± 16.33 | 1.4 ± 15.99 | -0.9 ± 16.16 | 1.0 ± 15.28 | 0.4 ± 15.68 | 0.4 ± 16.97 | 2.6 ± 16.42 | 1.6 ± 15.33 |
| Day 7 Observed | 84.5 ± 15.44 | 80.3 ± 12.44 | 83.4 ± 13.89 | 79.0 ± 13.45 | 80.0 ± 14.40 | 75.1 ± 13.69 | 74.3 ± 12.41 | 83.2 ± 13.11 | 76.9 ± 11.29 |
| Day 7 Change | 3.5 ± 18.07 | 0.2 ± 14.16 | -0.5 ± 16.23 | -4.9 ± 14.53 | -3.6 ± 16.19 | -8.6 ± 17.80 | -9.7 ± 16.75 | -0.5 ± 16.99 | -4.3 ± 12.54 |
| Day 8 Observed | — | — | — | — | — | — | — | 85.3 ± 15.03 | 80.7 ± 14.61 |
| Day 8 Change | — | — | — | — | — | — | — | 2.5 ± 18.08 | -2.9 ± 15.07 |
| Day 9 Observed | — | — | — | — | — | — | — | 90.7 ± 16.51 | 82.8 ± 15.66 |
| Day 9 Change | — | — | — | — | — | — | — | 6.8 ± 15.74 | -1.1 ± 14.94 |
| Day 10 Observed | — | — | — | — | — | — | — | 88.7 ± 15.73 | 85.1 ± 17.87 |
| Day 10 Change | — | — | — | — | — | — | — | 5.1 ± 17.47 | 1.6 ± 18.66 |
| Day 11 Observed | — | — | — | — | — | — | — | 89.3 ± 16.55 | 82.0 ± 16.84 |
| Day 11 Change | — | — | — | — | — | — | — | 6.4 ± 16.75 | -0.1 ± 17.81 |
| Day 12 Observed | — | — | — | — | — | — | — | 90.8 ± 16.25 | 80.0 ± 13.91 |
| 0Day 12 Change | — | — | — | — | — | — | — | 9.2 ± 17.91 | -1.4 ± 16.75 |
| Day 13 Observed | — | — | — | — | — | — | — | 86.6 ± 13.51 | 81.4 ± 13.21 |
| Day 13 Change | — | — | — | — | — | — | — | 6.2 ± 17.17 | 1.1 ± 15.14 |
| Day 14 Observed | — | — | — | — | — | — | — | 87.0 ± 17.66 | — |
| Day 14 Change | — | — | — | — | — | — | — | 7.2 ± 19.63 | — |
The C-SSRS measures both suicidal ideation and suicidal behavior and will be completed to assess lifetime suicidality before first dose of study drug, 3.5 hours after first daily dose of study drug on in-clinic treatment days, and then once a day before dosing during outpatient treatment days. C-SSRS will also be assessed at end of study/discontinuation.
| Participants | OL: Lofexidine HCl |
|---|---|
| Suicidality | 30 |
| Suicidal ideation | 27 |
| Suicidal behavior | 12 |
| Emergence of suicidal ideation | 2 |
| Emergence of serious suicidal ideation | 0 |
| Worsening of suicidal ideation | 2 |
| Emergence of suicidal behavior | 0 |
Hematology Parameters with Shifts in ≥3% of Subjects from Screening to End of Study
| Participants | Below Baseline (End of Study) | Normal (End of Study) | Above Baseline (End of Study) |
|---|---|---|---|
| Hemoglobin (g/dL) : Below (Baseline) | 25 | 27 | 0 |
| Hemoglobin (g/dL) : Normal (Baseline) | 8 | 124 | 8 |
| Hemoglobin (g/dL) : Above (Baseline) | 0 | 1 | 9 |
| Hematocrit (%) : Below (Baseline) | 11 | 23 | 0 |
| Hematocrit (%) : Normal (Baseline) | 6 | 120 | 20 |
| Hematocrit (%) : Above (Baseline) | 0 | 10 | 12 |
| Platelet count (x10^9/L) : Below (Baseline) | 11 | 0 | 0 |
| Platelet count (x10^9/L) : Normal (Baseline) | 4 | 166 | 10 |
| Platelet count (x10^9/L) : Above (Baseline) | 0 | 4 | 2 |
| Erythrocytes (x10^12/L) : Below (Baseline) | 14 | 20 | 0 |
| Erythrocytes (x10^12/L) : Normal (Baseline) | 11 | 122 | 16 |
| Erythrocytes (x10^12/L) : Above (Baseline) | 0 | 8 | 11 |
| Erythrocytes distribution width (%) : Below (Baseline) | 0 | 0 | 0 |
| Erythrocytes distribution width (%) : Normal (Baseline) | 0 | 150 | 22 |
| Erythrocytes distribution width (%) : Above (Baseline) | 0 | 8 | 22 |
| Mean corpuscular volume (fL) : Below (Baseline) | 4 | 2 | 0 |
| Mean corpuscular volume (fL) : Normal (Baseline) | 0 | 173 | 6 |
| Mean corpuscular volume (fL) : Above (Baseline) | 0 | 4 | 13 |
| Leukocytes (x10^9/L) : Below (Baseline) | 0 | 2 | 0 |
| Leukocytes (x10^9/L) : Normal (Baseline) | 2 | 167 | 23 |
| Leukocytes (x10^9/L) : Above (Baseline) | 0 | 4 | 4 |
| Neutrophils/Leukocytes (%) : Below (Baseline) | 0 | 4 | 0 |
| Neutrophils/Leukocytes (%) : Normal (Baseline) | 2 | 163 | 19 |
| Neutrophils/Leukocytes (%) : Above (Baseline) | 0 | 8 | 6 |
| Neutrophils (x10^9/L) : Below (Baseline) | 0 | 0 | 0 |
| Neutrophils (x10^9/L) : Normal (Baseline) | 1 | 182 | 13 |
| Neutrophils (x10^9/L) : Above (Baseline) | 0 | 3 | 3 |
| Lymphocytes/Leukocytes (%) : Below (Baseline) | 23 | 15 | 1 |
| Lymphocytes/Leukocytes (%) : Normal (Baseline) | 32 | 103 | 10 |
| Lymphocytes/Leukocytes (%) : Above (Baseline) | 1 | 12 | 5 |
| Lymphocytes, absolute (x10^9/L) : Below (Baseline) | 1 | 2 | 0 |
| Lymphocytes, absolute (x10^9/L) : Normal (Baseline) | 3 | 192 | 2 |
| Lymphocytes, absolute (x10^9/L) : Above (Baseline) | 0 | 1 | 1 |
| Monocytes/Leukocytes (%) : Below (Baseline) | 0 | 0 | 0 |
| Monocytes/Leukocytes (%) : Normal (Baseline) | 1 | 159 | 19 |
| Monocytes/Leukocytes (%) : Above (Baseline) | 0 | 17 | 6 |
| Monocytes (x10^9/L) : Below (Baseline) | 0 | 0 | 0 |
| Monocytes (x10^9/L) : Normal (Baseline) | 0 | 192 | 7 |
| Monocytes (x10^9/L) : Above (Baseline) | 0 | 2 | 1 |
| Eosinophils absolute (x10^9/L) : Below (Baseline) | 0 | 0 | 0 |
| Eosinophils absolute (x10^9/L) : Normal (Baseline) | 0 | 176 | 9 |
| Eosinophils absolute (x10^9/L) : Above (Baseline) | 0 | 10 | 7 |
| Eosinophils/Leukocytes (%) : Below (Baseline) | 0 | 0 | 0 |
| Eosinophils/Leukocytes (%) : Normal (Baseline) | 0 | 140 | 12 |
| Eosinophils/Leukocytes (%) : Above (Baseline) | 0 | 31 | 19 |
| Prothrombin time (seconds) : Below (Baseline) | 0 | 0 | 0 |
| Prothrombin time (seconds) : Normal (Baseline) | 0 | 154 | 20 |
| Prothrombin time (seconds) : Above (Baseline) | 0 | 17 | 14 |
| Activated Partial Thromboplastin Time (seconds) : Below (Baseline) | 0 | 1 | 0 |
| Activated Partial Thromboplastin Time (seconds) : Normal (Baseline) | 0 | 154 | 13 |
| Activated Partial Thromboplastin Time (seconds) : Above (Baseline) | 0 | 19 | 18 |
Chemistry Parameters with Shifts in ≥3% of Subjects from Screening to End of Study
| Participants | Below Baseline (End of Study) | Normal (End of Study) | Above Baseline (End of Study) |
|---|---|---|---|
| Alanine aminotransferase (U/L) : Below (Baseline) | 0 | 0 | 0 |
| Alanine aminotransferase (U/L) : Normal (Baseline) | 0 | 153 | 17 |
| Alanine aminotransferase (U/L) : Above (Baseline) | 0 | 12 | 22 |
| Aspartate Aminotransferase (U/L) : Below (Baseline) | 0 | 0 | 0 |
| Aspartate Aminotransferase (U/L) : Normal (Baseline) | 0 | 164 | 10 |
| Aspartate Aminotransferase (U/L) : Above (Baseline) | 0 | 16 | 14 |
| Gamma-glutamyl transferase (U/L) : Below (Baseline) | 9 | 13 | 0 |
| Gamma-glutamyl transferase (U/L) : Normal (Baseline) | 2 | 139 | 11 |
| Gamma-glutamyl transferase (U/L) : Above (Baseline) | 0 | 6 | 24 |
| Alkaline phosphatase (U/L) : Below (Baseline) | 6 | 3 | 0 |
| Alkaline phosphatase (U/L) : Normal (Baseline) | 9 | 170 | 3 |
| Alkaline phosphatase (U/L) : Above (Baseline) | 0 | 5 | 8 |
| Lactate dehydrogenase (U/L) : Below (Baseline) | 2 | 0 | 0 |
| Lactate dehydrogenase (U/L) : Normal (Baseline) | 3 | 164 | 7 |
| Lactate dehydrogenase (U/L) : Above (Baseline) | 0 | 19 | 9 |
| Blood urea nitrogen (mg/dL) : Below (Baseline) | 9 | 28 | 1 |
| Blood urea nitrogen (mg/dL) : Normal (Baseline) | 28 | 127 | 5 |
| Blood urea nitrogen (mg/dL) : Above (Baseline) | 1 | 4 | 1 |
| Creatinine (mg/dL) : Below (Baseline) | 29 | 17 | 0 |
| Creatinine (mg/dL) : Normal (Baseline) | 8 | 147 | 2 |
| Creatinine (mg/dL) : Above (Baseline) | 0 | 0 | 1 |
| Cholesterol (mg/dL) : Below (Baseline) | 0 | 0 | 0 |
| Cholesterol (mg/dL) : Normal (Baseline) | 0 | 153 | 18 |
| Cholesterol (mg/dL) : Above (Baseline) | 0 | 13 | 20 |
| Triglycerides (mg/dL) : Below (Baseline) | 0 | 0 | 0 |
| Triglycerides (mg/dL) : Normal (Baseline) | 0 | 107 | 40 |
| Triglycerides (mg/dL) : Above (Baseline) | 0 | 18 | 39 |
| Calcium (mg/dL) : Below (Baseline) | 1 | 9 | 0 |
| Calcium (mg/dL) : Normal (Baseline) | 7 | 182 | 3 |
| Calcium (mg/dL) : Above (Baseline) | 0 | 2 | 0 |
| Sodium (mEq/L) : Below (Baseline) | 3 | 6 | 0 |
| Sodium (mEq/L) : Normal (Baseline) | 3 | 187 | 5 |
| Sodium (mEq/L) : Above (Baseline) | 0 | 0 | 0 |
| Potassium (mEq/L) : Below (Baseline) | 0 | 2 | 0 |
| Potassium (mEq/L) : Normal (Baseline) | 2 | 183 | 11 |
| Potassium (mEq/L) : Above (Baseline) | 0 | 6 | 0 |
| Chloride (mEq/L) : Below (Baseline) | 0 | 5 | 0 |
| Chloride (mEq/L) : Normal (Baseline) | 3 | 190 | 5 |
| Chloride (mEq/L) : Above (Baseline) | 0 | 0 | 1 |
| Carbon dioxide (bicarbonate) (mEq/L) : Below (Baseline) | 0 | 0 | 0 |
| Carbon dioxide (bicarbonate) (mEq/L) : Normal (Baseline) | 3 | 134 | 7 |
| Carbon dioxide (bicarbonate) (mEq/L) : Above (Baseline) | 0 | 52 | 8 |
| Glucose (mg/dL) : Below (Baseline) | 0 | 5 | 0 |
| Glucose (mg/dL) : Normal (Baseline) | 1 | 130 | 35 |
| Glucose (mg/dL) : Above (Baseline) | 0 | 19 | 14 |
| Phosphate (mg/dL) : Below (Baseline) | 1 | 4 | 0 |
| Phosphate (mg/dL) : Normal (Baseline) | 6 | 138 | 22 |
| Phosphate (mg/dL) : Above (Baseline) | 1 | 26 | 6 |
| Protein (g/dL) : Below (Baseline) | 0 | 1 | 0 |
| Protein (g/dL) : Normal (Baseline) | 0 | 190 | 4 |
| Protein (g/dL) : Above (Baseline) | 0 | 6 | 3 |
| Thyroid Stimulating Hormone-3rd Generation (TSH Thyrotropin)(mU/L) : Below (Baseline) | 11 | 18 | 0 |
| Thyroid Stimulating Hormone-3rd Generation (TSH Thyrotropin)(mU/L) : Normal (Baseline) | 16 | 149 | 3 |
| Thyroid Stimulating Hormone-3rd Generation (TSH Thyrotropin)(mU/L) : Above (Baseline) | 0 | 6 | 1 |
| Participants | Below Baseline (End of Study) | Normal (End of Study) | Above Baseline (End of Study) |
|---|---|---|---|
| Erythrocytes (/HPF) : Below (Baseline) | 0 | 0 | 0 |
| Erythrocytes (/HPF) : Normal (Baseline) | 0 | 136 | 30 |
| Erythrocytes (/HPF) : Above (Baseline) | 0 | 28 | 13 |
| Leukocytes (/HPF) : Below (Baseline) | 0 | 0 | 0 |
| Leukocytes (/HPF) : Normal (Baseline) | 0 | 175 | 15 |
| Leukocytes (/HPF) : Above (Baseline) | 0 | 13 | 4 |
| Specific Gravity : Below (Baseline) | 0 | 2 | 0 |
| Specific Gravity : Normal (Baseline) | 0 | 188 | 3 |
| Specific Gravity : Above (Baseline) | 0 | 13 | 1 |
| pH : Below (Baseline) | 0 | 0 | 0 |
| pH : Normal (Baseline) | 0 | 204 | 1 |
| pH : Above (Baseline) | 0 | 2 | 0 |
For each 12-lead ECG obtained during the study, the investigator made an overall interpretation of the ECG (normal, abnormal NCS, and abnormal CS). Shifts from normal at baseline to abnormal NCS and abnormal CS at the end of study predose and postdose assessments were summarized.
| Participants | Baseline Finding: Normal (OL: Lofexidine HCl) | Baseline Finding: Abnormal (NCS) (OL: Lofexidine HCl) | Baseline Finding: Abnormal (CS) (OL: Lofexidine HCl) | Total (OL: Lofexidine HCl) |
|---|---|---|---|---|
| Day 1 Post 8am Dose — Normal | 139 | 16 | 0 | 155 |
| Day 1 Post 8am Dose — Abnormal (NCS) | 41 | 87 | 0 | 128 |
| Day 1 Post 8am Dose — Abnormal (CS) | 0 | 0 | 0 | 0 |
| End of Study Pre Dose — Normal | 83 | 20 | 0 | 103 |
| End of Study Pre Dose — Abnormal (NCS) | 19 | 38 | 0 | 57 |
| End of Study Pre Dose — Abnormal (CS) | 1 | 0 | 0 | 1 |
| End of Study Post Dose — Normal | 77 | 26 | 0 | 103 |
| End of Study Post Dose — Abnormal (NCS) | 41 | 47 | 0 | 88 |
| End of Study Post Dose — Abnormal (CS) | 2 | 0 | 0 | 2 |
Collected over AEs will be followed starting with dosing on Day 1 through Day 14, and will be evaluated as well on a 30-day post-last dose follow-up phone call.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OL: Lofexidine HCl | 0/286 (0%) | 2/286 (0.7%) | 270/286 (94.4%) |
| Event | OL: Lofexidine HCl |
|---|---|
| DelusionPsychiatric disorders | 1/286 |
| Cerebrovascular accidentNervous system disorders | 1/286 |
| Event | OL: Lofexidine HCl |
|---|---|
| InsomniaPsychiatric disorders | 144/286 |
| AnxietyPsychiatric disorders | 107/286 |
| Orthostatic hypotensionVascular disorders | 96/286 |
| HypotensionVascular disorders | 84/286 |
| BradycardiaCardiac disorders | 72/286 |
| DiarrheaGastrointestinal disorders | 54/286 |
| NauseaGastrointestinal disorders | 50/286 |
| DizzinessNervous system disorders | 47/286 |
| SedationNervous system disorders | 46/286 |
| HeadacheNervous system disorders | 43/286 |
| Age, Continuous(years) | OL: Lofexidine HCl |
|---|---|
| Mean | 37.5 ± 10.32 |
| Sex: Female, Male(Participants) | OL: Lofexidine HCl |
|---|---|
| Female | 98 |
| Male | 188 |
| Ethnicity (NIH/OMB)(Participants) | OL: Lofexidine HCl |
|---|---|
| Hispanic or Latino | 44 |
| Not Hispanic or Latino | 242 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | OL: Lofexidine HCl |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 62 |
| White | 218 |
| More than one race | 0 |
| Unknown or Not Reported | 5 |
| Height (cm)(cm) | OL: Lofexidine HCl |
|---|---|
| Mean | 173.2 ± 9.99 |
| Weight (kg)(kg) | OL: Lofexidine HCl |
|---|---|
| Mean | 78.4 ± 17.96 |
| BMI (kg/m^2)(kg/m^2) | OL: Lofexidine HCl |
|---|---|
| Mean | 26.1 ± 5.43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Sep 2015, 7 months.
Results were first posted in Apr 2021, 5 years 7 months after primary completion. A results delay was requested in Oct 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lofexidine
USWM, LLC (dba US WorldMeds)